EA201390722A1 - Лечение рака повышенными дозами растворимых белков слияния fgfr1 - Google Patents

Лечение рака повышенными дозами растворимых белков слияния fgfr1

Info

Publication number
EA201390722A1
EA201390722A1 EA201390722A EA201390722A EA201390722A1 EA 201390722 A1 EA201390722 A1 EA 201390722A1 EA 201390722 A EA201390722 A EA 201390722A EA 201390722 A EA201390722 A EA 201390722A EA 201390722 A1 EA201390722 A1 EA 201390722A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fgfr1
merger
cancer treatment
soluble proteins
patient
Prior art date
Application number
EA201390722A
Other languages
English (en)
Inventor
Харольд Кир
Original Assignee
Файв Прайм Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Файв Прайм Терапьютикс, Инк. filed Critical Файв Прайм Терапьютикс, Инк.
Publication of EA201390722A1 publication Critical patent/EA201390722A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Данное изобретение описывает способы лечения пациента, имеющего рак, включающие введение пациенту растворимого белка слияния рецептора фактора роста фибробластов 1 (FGFR1), такого как внеклеточного домена полипептида FGFR1, присоединенного к полипептиду Fc или другому партнеру слияния. Белок слияния может быть введен в дозе по меньшей мере приблизительно 2 мг/кг массы тела. В некоторых вариантах воплощения изобретения концентрация фактора роста фибробластов 2 (FGF-2) в плазме пациента составляет по меньшей мере 6 пг/мл. В некоторых вариантах воплощения изобретения рак характеризуется рецептором фактора роста фибробластов 2 (FGFR2), имеющим лиганд-зависимую активирующую мутацию.
EA201390722A 2010-11-15 2011-11-14 Лечение рака повышенными дозами растворимых белков слияния fgfr1 EA201390722A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41394010P 2010-11-15 2010-11-15
US42146210P 2010-12-09 2010-12-09
PCT/US2011/060661 WO2012068030A1 (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Publications (1)

Publication Number Publication Date
EA201390722A1 true EA201390722A1 (ru) 2013-11-29

Family

ID=44993965

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390722A EA201390722A1 (ru) 2010-11-15 2011-11-14 Лечение рака повышенными дозами растворимых белков слияния fgfr1
EA201390716A EA025828B1 (ru) 2010-11-15 2011-11-14 Комбинированная терапия внеклеточным доменом fgfr1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201390716A EA025828B1 (ru) 2010-11-15 2011-11-14 Комбинированная терапия внеклеточным доменом fgfr1

Country Status (14)

Country Link
EP (2) EP2640377B1 (ru)
JP (4) JP5945277B2 (ru)
KR (3) KR20130124513A (ru)
CN (2) CN107050426A (ru)
AU (2) AU2011329127B2 (ru)
BR (2) BR112013012041A2 (ru)
CA (2) CA2817583A1 (ru)
EA (2) EA201390722A1 (ru)
IL (2) IL226248A0 (ru)
MX (2) MX2013005388A (ru)
NZ (4) NZ703919A (ru)
SG (2) SG190788A1 (ru)
WO (2) WO2012068030A1 (ru)
ZA (2) ZA201303501B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US20130136740A1 (en) 2011-11-14 2013-05-30 Thomas Harding Methods of treating cancer
CN105188732A (zh) * 2013-05-01 2015-12-23 戊瑞治疗有限公司 治疗癌症的方法
KR20160013092A (ko) * 2013-05-23 2016-02-03 파이브 프라임 테라퓨틱스, 인크. 암을 치료하는 방법
CA2917268C (en) * 2013-07-05 2023-11-07 Integra Medical Inc. Oral compositions
WO2015066452A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
CN108602879A (zh) * 2016-02-04 2018-09-28 倪劲松 用于治疗疾病的抗体-药物协同作用技术

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
HU215581B (hu) 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3615220B2 (ja) 1990-07-06 2005-02-02 アヴェンティス ファーマシューティカルズ インコーポレイテッド 繊維芽細胞生育因子受容体
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
ES2256935T3 (es) 1997-04-07 2006-07-16 Genentech, Inc. Anticuerpos humanizadores y procedimiento para producirlos.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
BRPI0410745A (pt) 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
CN1829741A (zh) 2003-05-30 2006-09-06 健泰科生物技术公司 利用抗－vegf抗体的治疗
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
US20080286834A1 (en) 2005-01-27 2008-11-20 Robert Forgan Halenbeck Leader Sequences For Directing Secretion of Polypeptides and Methods For Production Thereof
JP4822371B1 (ja) 2005-07-22 2011-11-24 ファイブ プライム セラピューティクス， インコーポレイテッド Ｆｇｆｒ融合タンパク質によって疾患を治療するための組成物および方法
ES2366160T3 (es) * 2006-11-28 2011-10-17 Aventis Pharma S.A. Fusiones de fc con receptor para fgf soluble modificadas con actividad biológica mejorada.
CL2007003411A1 (es) * 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
AU2010319327B2 (en) * 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2

Also Published As

Publication number Publication date
SG190248A1 (en) 2013-06-28
JP5945277B2 (ja) 2016-07-05
EP2640406A1 (en) 2013-09-25
CA2817583A1 (en) 2012-05-24
JP2014500873A (ja) 2014-01-16
AU2011329127A1 (en) 2013-05-02
KR101910779B1 (ko) 2018-10-22
CN107050426A (zh) 2017-08-18
JP2013543870A (ja) 2013-12-09
KR20180053420A (ko) 2018-05-21
SG190788A1 (en) 2013-07-31
BR112013012040A2 (pt) 2016-08-16
MX2013005387A (es) 2013-10-17
KR20130124513A (ko) 2013-11-14
NZ610538A (en) 2015-02-27
IL226248A0 (en) 2013-07-31
CA2817537A1 (en) 2012-05-24
JP2017019843A (ja) 2017-01-26
EP2640377B1 (en) 2018-12-26
MX349293B (es) 2017-07-21
NZ703786A (en) 2016-08-26
BR112013012041A2 (pt) 2016-11-08
AU2011329125B2 (en) 2015-07-30
NZ610487A (en) 2015-03-27
JP2016196475A (ja) 2016-11-24
CN103347514B (zh) 2017-02-08
CN103347514A (zh) 2013-10-09
MX2013005388A (es) 2013-11-04
EA201390716A1 (ru) 2014-02-28
IL226252B (en) 2018-05-31
KR20130114676A (ko) 2013-10-18
ZA201303501B (en) 2016-07-27
WO2012068030A1 (en) 2012-05-24
WO2012068032A1 (en) 2012-05-24
JP6178240B2 (ja) 2017-08-09
NZ703919A (en) 2016-04-29
ZA201303573B (en) 2016-07-27
AU2011329127B2 (en) 2015-09-03
EP2640377A1 (en) 2013-09-25
EA025828B1 (ru) 2017-02-28
IL226252A0 (en) 2013-07-31
AU2011329125A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
US11912792B2 (en) Bicyclic peptide ligands specific for nectin-4
EA201390722A1 (ru) Лечение рака повышенными дозами растворимых белков слияния fgfr1
Zhang et al. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
CN105612175A (zh) 基于IL-15和IL-15Rαsushi结构域的调节因子
NZ608502A (en) Polypeptides that bind to human complement component c5
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
TW200634026A (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
RU2595857C2 (ru) Средство для профилактического и/или терапевтического лечения периферической нейропатической боли, вызываемой противораковым средством
JP2014500873A5 (ru)
WO2018068670A1 (zh) 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
ES2389474T3 (es) Conjugados para el tratamiento del mesotelioma
KR20190124247A (ko) Csf1r-기반 키메라 단백질
MX2014004132A (es) Señuelos humanos notch1.
EP3536337A1 (en) Therapeutic applications of smad7
Singh et al. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
EA200870535A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
WO2008097536A2 (en) Compositions and methods for treating psychiatric diseases and disorders
JP2021515779A (ja) Ｅｇｆｒ抗体によるｃｄ４７遮断療法における改善
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
Wang et al. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers
CN106336456A (zh) 一种cd33免疫原多肽及其用途
CN106659764A (zh) 环状鞘脂激活蛋白原肽及其用途
CN102070712B (zh) Vegf-a蛋白及其用途
EA045862B1 (ru) Бициклические пептидные лиганды, специфичные к нектину-4